<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280368</url>
  </required_header>
  <id_info>
    <org_study_id>1-16-02-191-14</org_study_id>
    <nct_id>NCT03280368</nct_id>
  </id_info>
  <brief_title>Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation</brief_title>
  <acronym>ARCADE</acronym>
  <official_title>Adherence and the Role of Coagulation Assays in Patients Treated With Dabigatran Etexilate for Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitalsenheden Vest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diagnostica Stago</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANIARA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospitalsenheden Vest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the
      level of adherence will be measured using a questionnaire, the Danish National Prescription
      Registry and pillcount and will be related to plasma levels of dabigatran measured by liquid
      chromatography tandem mass spectrometry (LC-MS/MS) and coagulation assays. The aim of the
      study is to measure the level of adherence and evaluate the usefulness of different
      coagulation assays to measure adherence in these patients. Furthermore, the aim is to
      determine the correlation between the anticoagulant effect of dabigatran using different
      coagulation assays and plasma levels of dabigatran.

      Most studies so far have been performed in vitro with plasma samples spiked with dabigatran.
      In this study the present knowledge from results of coagulation assays in dabigatran spiked
      plasma samples will be compared to the results of coagulation assays using blood samples from
      real-life patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medication adherence Stability after storage at -80 degrees C; correlation between plasma concentration and the anticoagulant effect of dabigatran</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by pillcount, bloodtests, the Danish National Prescription Registry and the Morisky Medication Adherence Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient treatment satisfaction</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by the Anticlot Treatment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication persistence</measure>
    <time_frame>2 years</time_frame>
    <description>Time from start to end of dabigatran treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>2 years</time_frame>
    <description>Creatinine and Glomerular Filtration Rate calculated by the Cockroft Gault formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects</measure>
    <time_frame>2 years</time_frame>
    <description>Bleeding, gastrointestinal side-effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dabigatran plasma concentrations</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by liquid-chromatography tandem mass spectrometry (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>2 years</time_frame>
    <description>kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>2 years</time_frame>
    <description>meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>2 years</time_frame>
    <description>centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>2 years</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>2 years</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROTEM</measure>
    <time_frame>2 years</time_frame>
    <description>Clotting time (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diluted thrombin time (calibrated for dabigatran)</measure>
    <time_frame>2 years</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ecarin chromogenic assay</measure>
    <time_frame>2 years</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">430</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Medication Adherence</condition>
  <condition>Blood Coagulation Tests</condition>
  <condition>Anticoagulants; Circulating, Hemorrhagic Disorder</condition>
  <condition>Drug Effect</condition>
  <condition>Drug Use</condition>
  <condition>Drug Toxicity</condition>
  <condition>Drug Intolerance</condition>
  <condition>Blood Clot</condition>
  <condition>Blood Coagulation Disorder</condition>
  <condition>Laboratory Problem</condition>
  <condition>Bleeding</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>A healthy volunteers</arm_group_label>
    <description>Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A patients</arm_group_label>
    <description>Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.
Inclusion before initiation of anticoagulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bloodtest</intervention_name>
    <arm_group_label>A healthy volunteers</arm_group_label>
    <arm_group_label>A patients</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation with an indication for initiation of dabigatran etexilate
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Non-valvular atrial fibrillation

          -  Indication for dabigatran etexilate

        Exclusion Criteria:

          -  Use of anticoagulant medication within the last month

          -  Contra-indication to dabigatran etexilate

          -  Unable or not wishing to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willemijn Comuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitalsenheden Vest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steen Husted, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospitalsenheden Vest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Unit West</name>
      <address>
        <city>Herning</city>
        <state>Mid-Jutland</state>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Comuth WJ, de Maat MPM, van de Kerkhof D, Malczynski J, Husted S, Kristensen SD, Münster AB. Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion. Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):91-99. doi: 10.1093/ehjcvp/pvy047. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):99.</citation>
    <PMID>30608563</PMID>
  </results_reference>
  <results_reference>
    <citation>Comuth WJ, Lauridsen HH, Kristensen SD, Münster AB. Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale. TH Open. 2018 Sep 13;2(3):e280-e290. doi: 10.1055/s-0038-1670631. eCollection 2018 Jul.</citation>
    <PMID>31249952</PMID>
  </results_reference>
  <results_reference>
    <citation>Comuth WJ, Henriksen LØ, van de Kerkhof D, Husted SE, Kristensen SD, de Maat MPM, Münster AB. Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration. Thromb Res. 2018 Apr;164:32-39. doi: 10.1016/j.thromres.2018.02.141. Epub 2018 Feb 17.</citation>
    <PMID>29475179</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitalsenheden Vest</investigator_affiliation>
    <investigator_full_name>Willemijn Comuth</investigator_full_name>
    <investigator_title>Cardiologist, PhD-fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

